Patient characteristics
| Characteristics . | Total, N (%) N = 585 . | PTCy-based, n (%) n = 272 . | Non-PTCy, n (%) n = 313 . | P . |
|---|---|---|---|---|
| Sex Female Male | 243 (42) 342 (58) | 120 (44) 152 (56) | 123 (39) 190 (61) | 0.2 |
| Age, median (interquartile range) years Age >55 Age ≤55 | 57 (18-77) 309 (53) 276 (47) | 61 (18-77) 180 (66) 92 (34) | 50 (18-74) 129 (41) 184 (59) | <.001 <.001 |
| Diagnosis AML/MDS Acute lymphocytic leukemia CML/MPD Chronic lymphocytic leukemia Lymphoma Other | 327 (56) 76 (13) 82 (14) 24 (4) 52 (9) 24 (4) | 189 (69) 9 (3) 50 (18) 4 (1) 12 (4) 8 (3) | 138 (44) 67 (21) 32 (10) 20 (6) 40 (13) 16 (5) | <.001 |
| Donor type MUD MRD | 365 (62) 220 (38) | 179 (66) 93 (34) | 186 (59) 127 (41) | .1 |
| Stem cell source Peripheral blood Bone marrow | 475 (81) 110 (19) | 229 (84) 43 (16) | 246 (79) 67 (21) | .08 |
| Disease status Active Remission | 356 (61) 229 (39) | 179 (66) 93 (34) | 177 (57) 136 (43) | .02 |
| Preparative regimen Reduced intensity Myeloablative | 201 (34) 384 (66) | 82 (30) 190 (70) | 119 (38) 194 (62) | .05 |
| History of anthracycline Yes No | 335 (57) 250 (43) | 122 (45) 150 (55) | 113 (36) 200 (64) | <.001 |
| History of HTN Yes No | 235 (40) 350 (60) | 81 (30) 191 (70) | 114 (36) 199 (64) | .03 |
| History of hyperlipidemia Yes No | 115 (20) 470 (80) | 60 (22) 212 (78) | 55 (18) 258 (82) | .2 |
| Smoker Yes No Missing | 227 (39) 356 (61) 2 (0) | 112 (41) 160 (59) 0 (0) | 115 (37) 196 (63) 2 (1) | .4 |
| Karnofsky Performance Scale <90 ≥90 Missing | 230 (39) 287 (49) 68 (12) | 117 (43) 133 (49) 22 (8) | 113 (36) 154 (49) 46 (15) | .3 |
| HCT-CI >3 ≤3 | 195 (33) 390 (67) | 81 (30) 191 (70) | 114 (36) 199 (64) | .09 |
| Cardiac* Yes No | 54 (8) 531 (92) | 22 (8) 250 (92) | 32 (10) 281 (90) | .4 |
| Arrhythmia† Yes No | 39 (7) 546 (93) | 17 (6) 255 (94) | 22 (7) 291 (93) | .7 |
| Heart valve‡ Yes No | 11 (2) 574 (98) | 5 (2) 267 (98) | 6 (2) 307(98) | .6 |
| Diabetes Yes No | 63 (11) 522 (89) | 30 (11) 242 (89) | 33 (11) 280 (89) | .8 |
| Pulmonary 0 2 3 | 335 (57) 190 (33) 60 (10) | 166 (61) 82 (30) 24(9) | 169 (54) 108 (34) 36 (11) | .2 |
| Obesity Yes No | 76 (13) 509 (87) | 38 (14) 234 (86) | 38 (12) 275 (88) | .5 |
| Infection Yes No | 78 (13) 507 (87) | 26 (10) 246(90) | 52 (17) 267 (83) | .01 |
| Hepatic 0 1 3 | 423 (72) 123 (21) 39 (7) | 197 (72) 59 (22) 16 (6) | 226 (72) 64 (20) 23 (7) | .7 |
| Characteristics . | Total, N (%) N = 585 . | PTCy-based, n (%) n = 272 . | Non-PTCy, n (%) n = 313 . | P . |
|---|---|---|---|---|
| Sex Female Male | 243 (42) 342 (58) | 120 (44) 152 (56) | 123 (39) 190 (61) | 0.2 |
| Age, median (interquartile range) years Age >55 Age ≤55 | 57 (18-77) 309 (53) 276 (47) | 61 (18-77) 180 (66) 92 (34) | 50 (18-74) 129 (41) 184 (59) | <.001 <.001 |
| Diagnosis AML/MDS Acute lymphocytic leukemia CML/MPD Chronic lymphocytic leukemia Lymphoma Other | 327 (56) 76 (13) 82 (14) 24 (4) 52 (9) 24 (4) | 189 (69) 9 (3) 50 (18) 4 (1) 12 (4) 8 (3) | 138 (44) 67 (21) 32 (10) 20 (6) 40 (13) 16 (5) | <.001 |
| Donor type MUD MRD | 365 (62) 220 (38) | 179 (66) 93 (34) | 186 (59) 127 (41) | .1 |
| Stem cell source Peripheral blood Bone marrow | 475 (81) 110 (19) | 229 (84) 43 (16) | 246 (79) 67 (21) | .08 |
| Disease status Active Remission | 356 (61) 229 (39) | 179 (66) 93 (34) | 177 (57) 136 (43) | .02 |
| Preparative regimen Reduced intensity Myeloablative | 201 (34) 384 (66) | 82 (30) 190 (70) | 119 (38) 194 (62) | .05 |
| History of anthracycline Yes No | 335 (57) 250 (43) | 122 (45) 150 (55) | 113 (36) 200 (64) | <.001 |
| History of HTN Yes No | 235 (40) 350 (60) | 81 (30) 191 (70) | 114 (36) 199 (64) | .03 |
| History of hyperlipidemia Yes No | 115 (20) 470 (80) | 60 (22) 212 (78) | 55 (18) 258 (82) | .2 |
| Smoker Yes No Missing | 227 (39) 356 (61) 2 (0) | 112 (41) 160 (59) 0 (0) | 115 (37) 196 (63) 2 (1) | .4 |
| Karnofsky Performance Scale <90 ≥90 Missing | 230 (39) 287 (49) 68 (12) | 117 (43) 133 (49) 22 (8) | 113 (36) 154 (49) 46 (15) | .3 |
| HCT-CI >3 ≤3 | 195 (33) 390 (67) | 81 (30) 191 (70) | 114 (36) 199 (64) | .09 |
| Cardiac* Yes No | 54 (8) 531 (92) | 22 (8) 250 (92) | 32 (10) 281 (90) | .4 |
| Arrhythmia† Yes No | 39 (7) 546 (93) | 17 (6) 255 (94) | 22 (7) 291 (93) | .7 |
| Heart valve‡ Yes No | 11 (2) 574 (98) | 5 (2) 267 (98) | 6 (2) 307(98) | .6 |
| Diabetes Yes No | 63 (11) 522 (89) | 30 (11) 242 (89) | 33 (11) 280 (89) | .8 |
| Pulmonary 0 2 3 | 335 (57) 190 (33) 60 (10) | 166 (61) 82 (30) 24(9) | 169 (54) 108 (34) 36 (11) | .2 |
| Obesity Yes No | 76 (13) 509 (87) | 38 (14) 234 (86) | 38 (12) 275 (88) | .5 |
| Infection Yes No | 78 (13) 507 (87) | 26 (10) 246(90) | 52 (17) 267 (83) | .01 |
| Hepatic 0 1 3 | 423 (72) 123 (21) 39 (7) | 197 (72) 59 (22) 16 (6) | 226 (72) 64 (20) 23 (7) | .7 |
CML/MPD, chronic myeloid leukemia/myeloproliferative disease.
Cardiac includes coronary artery disease (≥1 vessel with coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, or ejection fraction ≤50%.
Arrhythmia, atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias.
Heart valve, any heart valve disease except mitral valve prolapse.